Mahdal M, Jindra J, Staniczková Zambo I, Pazourek L, Nachtnebl L, Tomáš T
I. ortopedická klinika Fakultní nemocnice u sv. Anny v Brně, Lékařská fakulta Masarykovy univerzity, Brno.
Ústav patologie, Fakultní nemocnice u sv. Anny v Brně, Lékařská fakulta Masarykovy univerzity, Brno.
Acta Chir Orthop Traumatol Cech. 2022;89(3):188-192.
PURPOSE OF THE STUDY The preferred treatment of giant cell tumor of bone is curettage with the use of local adjuvant. If the tumor spreads beyond the bone into soft tissues, en bloc excision should be performed. Intralesional curettage allows joint preservation, but it is associated with a high recurrence rate. The purpose of the study was to identify the risk factors for local recurrence and to compare the functional outcomes after both types of surgical procedures. MATERIAL AND METHODS The group included 16 patients (5 women, 11 men) with giant cell tumor of bone in distal forearm treated at the First Department of Orthopedic Surgery, St. Anne s University Hospital Brno in 2005-2019. The mean age of patients was 38 years (22-53). The follow-up period was 6.75 years (2-15) on average. The most common location of the tumor was distal radius (14). In 6 patients denosumab treatment was indicated. Based on the obtained data, we compared the effects of gender, Campanacci grade, type of surgery and administration of denosumab on the risk of local recurrence. The functional outcomes were evaluated retrospectively based on the Musculoskeletal Tumor Society scoring system for upper limb salvage surgeries. RESULTS Resection and reconstruction using an osteocartilaginous allograft was performed in 9 patients. Seven patients were treated with tumor curettage with bone cement used to fill the cavity. The group of patients who underwent curettage showed a significantly higher mean MSTS score 89% compared to the group of patients with resection with the mean MSTS score 66% (P < 0.05). Local tumor recurrence was reported in 3 patients (18.75%). No statistically significant difference was found in gender, tumor grade, radicality of surgery or administration of targeted therapy with respect to the incidence of local recurrence. Altogether 6 complications (37.5%) were observed in the group. DISCUSSION The treatment of a giant cell tumor of bone aims to completely remove the tumor and to preserve the best possible function of the limb. The complications in distal forearm involve particularly an increase incidence of local recurrence and painful or limited range of motion of the wrist. Whereas curettage with the use of local adjuvant is burdened with a higher recurrence rate, resection with allograft reconstruction of bone defect is usually associated with poorer functional outcomes. CONCLUSIONS Tumor curettage using local adjuvant is preferred in a well-circumscribed tumor and offers an excellent functional outcome. En bloc tumor resection and reconstruction using an osteocartilaginous allograft is a suitable treatment option for a locally advanced tumor with a low risk of local recurrence. Key words: giant cell tumor of bone, distal radius, distal ulna, curettage, osteocartilaginous allograft.
研究目的 骨巨细胞瘤的首选治疗方法是刮除术并使用局部辅助治疗。如果肿瘤扩散至骨外软组织,则应进行整块切除。病灶内刮除术可保留关节,但复发率较高。本研究的目的是确定局部复发的危险因素,并比较两种手术方式后的功能结果。
材料与方法 该组包括16例2005年至2019年在布尔诺圣安妮大学医院第一骨外科接受治疗的前臂远端骨巨细胞瘤患者(5名女性,11名男性)。患者的平均年龄为38岁(22 - 53岁)。平均随访期为6.75年(2 - 15年)。肿瘤最常见的部位是桡骨远端(14例)。6例患者接受了地诺单抗治疗。根据获得的数据,我们比较了性别、坎帕纳奇分级、手术类型和地诺单抗给药对局部复发风险的影响。根据肌肉骨骼肿瘤学会上肢保肢手术评分系统对功能结果进行回顾性评估。
结果 9例患者采用骨软骨异体移植进行切除和重建。7例患者接受肿瘤刮除术并用骨水泥填充骨腔。接受刮除术的患者组的平均肌肉骨骼肿瘤学会(MSTS)评分显著高于切除组,分别为89%和66%(P < 0.05)。3例患者(18.75%)出现局部肿瘤复发。在性别、肿瘤分级、手术根治性或靶向治疗给药方面,局部复发发生率未发现统计学显著差异。该组共观察到6例并发症(37.5%)。
讨论 骨巨细胞瘤的治疗旨在完全切除肿瘤并保留肢体尽可能好的功能。前臂远端的并发症尤其包括局部复发率增加以及腕关节疼痛或活动范围受限。虽然使用局部辅助的刮除术复发率较高,但骨缺损异体移植重建的切除术通常功能结果较差。
结论 对于边界清楚的肿瘤,使用局部辅助的肿瘤刮除术是首选,且功能结果良好。使用骨软骨异体移植进行肿瘤整块切除和重建是局部晚期肿瘤且局部复发风险低的合适治疗选择。
骨巨细胞瘤;桡骨远端;尺骨远端;刮除术;骨软骨异体移植